Biovec B.V.
Records under this name other than patents Biovec B.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,420,075 | Ex Vivo and in Vivo Expression of the Thrombomodulin Gene for the Treatment of Cardiovascular and Peripheral Vascular Diseases Formerly held Lapsed on the fee record Ended Apr 16, 2021 · High confidence | Lapsed on the fee record | Ended Apr 16, 2021 | High confidence |
| US 7,501,114 | Ex Vivo and in Vivo Expression of the Thrombomodulin Gene for the Treatment of Cardiovascular and Peripheral Vascular Diseases Formerly held Lapsed on the fee record Ended Mar 10, 2021 · High confidence | Lapsed on the fee record | Ended Mar 10, 2021 | High confidence |
| US 8,367,056 | In Vivo and Ex Vivo Gene Transfer into Renal Tissue Using Gutless Adenovirus Vectors Formerly held Lapsed on the fee record Ended Feb 5, 2021 · Medium confidence | Lapsed on the fee record | Ended Feb 5, 2021 | Medium confidence |
| US 7,481,998 | Ex Vivo and in Vivo Expression of the Thrombomodulin Gene for the Treatment of Cardiovascular and Peripheral Vascular Diseases Formerly held Lapsed on the fee record Ended Jan 27, 2021 · High confidence | Lapsed on the fee record | Ended Jan 27, 2021 | High confidence |
| US 8,242,095 | In Vivo and Ex Vivo Gene Transfer into Renal Tissue Using Gutless Adenovirus Vectors Formerly held Lapsed on the fee record Ended Aug 14, 2020 · Medium confidence | Lapsed on the fee record | Ended Aug 14, 2020 | Medium confidence |
| US 8,236,300 | In Vivo and Ex Vivo Gene Transfer into Renal Tissue Using Gutless Adenovirus Vectors Formerly held Lapsed on the fee record Ended Aug 7, 2020 · Low confidence | Lapsed on the fee record | Ended Aug 7, 2020 | Low confidence |
| US 8,048,410 | In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors Formerly held Lapsed on the fee record Ended Nov 1, 2019 · From the USPTO record | Lapsed on the fee record | Ended Nov 1, 2019 | From the USPTO record |
| US 7,179,459 | Ex Vivo and in Vivo Expression of the Thrombomodulin Gene for the Treatment of Cardiovascular and Peripheral Vascular Diseases Formerly held Lapsed on the fee record Ended Feb 20, 2019 · High confidence | Lapsed on the fee record | Ended Feb 20, 2019 | High confidence |
| US 7,803,365 | Ex Vivo and in Vivo Expression of the Thrombomodulin Gene for the Treatment of Cardiovascular and Peripheral Vascular Diseases Formerly held Lapsed on the fee record Ended Sep 28, 2018 · High confidence | Lapsed on the fee record | Ended Sep 28, 2018 | High confidence |
| US 7,713,522 | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases Formerly held Lapsed on the fee record Ended May 11, 2018 · From the USPTO record | Lapsed on the fee record | Ended May 11, 2018 | From the USPTO record |